NCT02447640View on ClinicalTrials.gov

PET Imaging Study to Evaluate the mGlu5r Occupancy Following ADX48621 (Dipraglurant) Administration

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Healthy
Interventions
DRUG

ADX48621

ADX4862, an investigational compound, is a potent, selective, negative allosteric modulator of the metabotropic glutamate receptor 5 (mGlu5 NAM).

RADIATION

[18F]FPEB

radiotracer used for PET scanning

Trial Locations (1)

21287

Johns Hopkins Hospital, Baltimore

Sponsors

Collaborators (1)

Addex Pharma S.A.
All Listed Sponsors
collaborator

Addex Pharma S.A.

INDUSTRY

lead

Johns Hopkins University

OTHER

NCT02447640 - PET Imaging Study to Evaluate the mGlu5r Occupancy Following ADX48621 (Dipraglurant) Administration | Biotech Hunter | Biotech Hunter